Literature DB >> 12734906

Quality of life in women with fibromyalgia syndrome: validation of the QIF, the French version of the fibromyalgia impact questionnaire.

Serge Perrot1, Dominique Dumont, Francis Guillemin, Jacques Pouchot, Joël Coste.   

Abstract

OBJECTIVE: To validate a translated and adapted version of the Fibromyalgia Impact Questionnaire (FIQ) for use in French-speaking populations.
METHODS: The FIQ was translated into French by 2 independent translators and then back-translated into English to assess the conceptual equivalence. The translated version was tested and adapted by an expert committee to obtain the Questionnaire de mesure d'Impact de la Fibromyalgie (QIF), the French version of the FIQ. We administered the QIF to 102 women with fibromyalgia (FM): 71 women who consulted once, and 31 women who were follow for 3 visits (D0, M1, and M3). The patients were also asked to answer 4 other questionnaires: the McGill Pain Questionnaire, the Medical Outcome Study Short Form-36 (SF-36), the short form of the Arthritis Impact Measurement Scale 2 (AIMS2), and the General Health Questionnaire (GHQ) (for psychiatric assessment). To ensure test-retest reliability, the patients were asked to complete the QIF 7 days after the first visit and to send it back to the investigators by mail. During each visit, all patients were asked about pain intensity. A tender point count was obtained by thumb palpation and the tenderness threshold of each specific point was assessed by a 4-point scale score to determine the global tender point index.
RESULTS: No major cultural adaptation was needed to obtain the French version of the FIQ. Test-retest reliability coefficients (intraclass correlation coefficient) for each question ranged from 0.04 to 0.84. Two items from the QIF (number of days when the patient felt good and visual analog scale stiffness) did not reach significant levels of test-retest reliability. Internal validity was good. The QIF score correlated well with the SF-36 and AIMS2 scores. The psychological aspects of the QIF were well correlated with those of GHQ-28. None of the items from the McGill Pain Questionnaire was correlated with QIF items. Similarly the clinical data concerning pain assessment were not correlated with QIF items.
CONCLUSIONS: QIF is a valid instrument for measuring functional disability and health status in French women with FM. Some of the items were of a limited reliability, perhaps due to the variability of the multiple aspects of this syndrome.

Entities:  

Mesh:

Year:  2003        PMID: 12734906

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  14 in total

1.  Fibromyalgia subgroups: profiling distinct subgroups using the Fibromyalgia Impact Questionnaire. A preliminary study.

Authors:  Juliana Barcellos de Souza; Philippe Goffaux; Nancy Julien; Stephane Potvin; Jacques Charest; Serge Marchand
Journal:  Rheumatol Int       Date:  2008-09-27       Impact factor: 2.631

2.  Validation of a Persian version of the Fibromyalgia Impact Questionnaire (FIQ-P).

Authors:  Ali Bidari; Morteza Hassanzadeh; Mohamad-Farzam Mohabat; Elham Talachian; Effat Merghati Khoei
Journal:  Rheumatol Int       Date:  2013-10-29       Impact factor: 2.631

3.  Temporal summation of pain is not amplified in a large proportion of fibromyalgia patients.

Authors:  Stéphane Potvin; Emilie Paul-Savoie; Mélanie Morin; Patricia Bourgault; Serge Marchand
Journal:  Pain Res Treat       Date:  2012-06-03

4.  Multicomponent interdisciplinary group intervention for self-management of fibromyalgia: a mixed-methods randomized controlled trial.

Authors:  Patricia Bourgault; Anaïs Lacasse; Serge Marchand; Roxanne Courtemanche-Harel; Jacques Charest; Isabelle Gaumond; Juliana Barcellos de Souza; Manon Choinière
Journal:  PLoS One       Date:  2015-05-15       Impact factor: 3.240

5.  Lower Functional Connectivity of the Periaqueductal Gray Is Related to Negative Affect and Clinical Manifestations of Fibromyalgia.

Authors:  Marie-Andrée Coulombe; Keith St Lawrence; Dwight E Moulin; Patricia Morley-Forster; Mahsa Shokouhi; Warren R Nielson; Karen D Davis
Journal:  Front Neuroanat       Date:  2017-06-08       Impact factor: 3.856

6.  Osteopathic medicine for fibromyalgia: a sham-controlled randomized clinical trial.

Authors:  Joël Coste; Terkia Medkour; Jean-Yves Maigne; Marc Pérez; Françoise Laroche; Serge Perrot
Journal:  Ther Adv Musculoskelet Dis       Date:  2021-04-16       Impact factor: 5.346

7.  Cross-cultural adaptation and validation of a Bengali version of the modified fibromyalgia impact questionnaire.

Authors:  Mohammed A Muquith; Md Nazrul Islam; Syed A Haq; Peter M Ten Klooster; Johannes J Rasker; Muhammad B Yunus
Journal:  BMC Musculoskelet Disord       Date:  2012-08-27       Impact factor: 2.362

8.  Health-resource use and costs associated with fibromyalgia in France, Germany, and the United States.

Authors:  Tyler Knight; Caroline Schaefer; Arthi Chandran; Gergana Zlateva; Andreas Winkelmann; Serge Perrot
Journal:  Clinicoecon Outcomes Res       Date:  2013-04-23

9.  Is the deficit in pain inhibition in fibromyalgia influenced by sleep impairments?

Authors:  Emilie Paul-Savoie; Serge Marchand; Mélanie Morin; Patricia Bourgault; Nathalie Brissette; Vongmaly Rattanavong; Christian Cloutier; Alain Bissonnette; Stéphane Potvin
Journal:  Open Rheumatol J       Date:  2012-10-04

10.  Fibromyalgia in the workplace: risk factors for sick leave are related to professional context rather than fibromyalgia characteristics- a French national survey of 955 patients.

Authors:  F Laroche; D Azoulay; A P Trouvin; J Coste; S Perrot
Journal:  BMC Rheumatol       Date:  2019-10-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.